International Neurourology Journal

Korean Continence Society (대한배뇨장애요실금학회)
권호 표지
DOI QR코드

DOI QR Code

Comprehensive MicroRNAome Analysis of the Relationship Between Alzheimer Disease and Cancer in PSEN Double-Knockout Mice

  • Ham, Suji (Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST)) ;
  • Kim, Tae Kyoo (Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST)) ;
  • Ryu, Jeewon (Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST)) ;
  • Kim, Yong Sik (Department of Pharmacology, Seoul National University College of Medicine) ;
  • Tang, Ya-Ping (Neuroscience Center of Excellence, Louisiana State University Health Sciences Center) ;
  • Im, Heh-In (Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology (KIST))
  • Received : 2018.12.04
  • Accepted : 2018.12.12
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Presenilins are functionally important components of ${\gamma}$-secretase, which cleaves a number of transmembrane proteins. Manipulations of PSEN1 and PSEN2 have been separately studied in Alzheimer disease (AD) and cancer because both involve substrates of ${\gamma}$-secretase. However, numerous clinical studies have reported an inverse correlation between AD and cancer. Interestingly, AD is a neurodegenerative disorder, whereas cancer is characterized by the proliferation of malignant cells. However, this inverse correlation in the PSEN double-knockout (PSEN dKO) mouse model of AD has been not elucidated, although doing so would shed light onto the relationship between AD and cancer. Methods: To investigate the inverse relationship of AD and cancer under conditions of PSEN loss, we used the hippocampus of 7-month-old and 18-month-old PSEN dKO mice for a microRNA (miRNA) microarray analysis, and explored the tumorsuppressive or oncogenic role of differentially-expressed miRNAs. Results: The total number of miRNAs that showed changes in expression level was greater at 18 months of age than at 7 months. Most of the putative target genes of the differentially-expressed miRNAs involved Cancer pathways. Conclusions: Based on literature reviews, many of the miRNAs involved in Cancer pathways were found to be known tumorsuppressive miRNAs, and their target genes were known or putative oncogenes. In conclusion, the expression levels of known tumor-suppressive miRNAs increased at 7 and 18 months, in the PSEN dKO mouse model of AD, supporting the negative correlation between AD and cancer.

Keywords

Acknowledgement

Supported by : National Research Council of Science & Technology (NST), National Research Foundation of Korea

References

  1. Yonemura Y, Futai E, Yagishita S, Suo S, Tomita T, Iwatsubo T, et al. Comparison of presenilin 1 and presenilin 2 ${\gamma}$-secretase activities using a yeast reconstitution system. J Biol Chem 2011;286:44569-75. https://doi.org/10.1074/jbc.M111.270108
  2. Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004;5:499-504. https://doi.org/10.1038/nrm1406
  3. Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 2001;31:713-26. https://doi.org/10.1016/S0896-6273(01)00417-2
  4. Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 2015;85:967-81. https://doi.org/10.1016/j.neuron.2015.02.010
  5. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 1999;96:11872-7. https://doi.org/10.1073/pnas.96.21.11872
  6. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004;42:23-36. https://doi.org/10.1016/S0896-6273(04)00182-5
  7. Ham S, Kim TK, Lee S, Tang YP, Im HI. MicroRNA Profiling in aging brain of PSEN1/PSEN2 double knockout mice. Mol Neurobiol 2018;55:5232-42. https://doi.org/10.1007/s12035-017-0753-6
  8. Ham S, Kim TK, Hong H, Kim YS, Tang YP, Im HI. Big data analysis of genes associated with neuropsychiatric disorders in an Alzheimer's disease animal model. Front Neurosci 2018;12:407. https://doi.org/10.3389/fnins.2018.00407
  9. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-51. https://doi.org/10.1038/nrc3035
  10. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9. https://doi.org/10.1038/onc.2008.343
  11. Yun HM, Park MH, Kim DH, Ahn YJ, Park KR, Kim TM, et al. Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development. Oncogene 2014;33:5193-200. https://doi.org/10.1038/onc.2014.128
  12. Rocher-Ros V, Marco S, Mao JH, Gines S, Metzger D, Chambon P, et al. Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene 2010;29:2950-61. https://doi.org/10.1038/onc.2010.57
  13. Li P, Lin X, Zhang JR, Li Y, Lu J, Huang FC, et al. The expression of presenilin 1 enhances carcinogenesis and metastasis in gastric cancer. Oncotarget 2016;7:10650-62.
  14. Behrens MI, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer's disease? Curr Alzheimer Res 2009;6:196-204. https://doi.org/10.2174/156720509788486608
  15. Tabares-Seisdedos R, Rubenstein JL. Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci 2013;14:293-304. https://doi.org/10.1038/nrn3464
  16. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 2004;101:2173-8. https://doi.org/10.1073/pnas.0308512100
  17. Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer N, et al. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 2006;26:6377-85. https://doi.org/10.1523/JNEUROSCI.0651-06.2006
  18. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015;12;4. doi: 10.7554/eLife.05005.
  19. Wang X. Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-ligation studies. Bioinformatics 2016;32:1316-22. https://doi.org/10.1093/bioinformatics/btw002
  20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57. https://doi.org/10.1038/nprot.2008.211
  21. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13. https://doi.org/10.1093/nar/gkn923
  22. Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, et al. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A 2001;98:10863-8. https://doi.org/10.1073/pnas.191284198
  23. Park MH, Yun HM, Hwang CJ, Park SI, Han SB, Hwang DY, et al. Presenilin mutation suppresses lung tumorigenesis via inhibition of peroxiredoxin 6 activity and expression. Theranostics 2017;7:3624-37. https://doi.org/10.7150/thno.21408
  24. To MD, Gokgoz N, Doyle TG, Donoviel DB, Knight JA, Hyslop PS, et al. Functional characterization of novel presenilin-2 variants identified in human breast cancers. Oncogene 2006;25:3557-64. https://doi.org/10.1038/sj.onc.1209397
  25. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 2013;18:282-9. https://doi.org/10.1016/j.drudis.2012.10.002
  26. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14. https://doi.org/10.1038/nrg2634
  27. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008;105:3903-8. https://doi.org/10.1073/pnas.0712321105
  28. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol 2011;39:13-21.
  29. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or overexpression of plateletderived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-3.
  30. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7. https://doi.org/10.1038/nature09626

Cited by

  1. New Platform for the Direct Profiling of microRNAs in Biofluids vol.91, pp.9, 2018, https://doi.org/10.1021/acs.analchem.9b00213
  2. Therapeutic Study of Phytochemicals Against Cancer and Alzheimer’s Disease Management vol.20, pp.13, 2018, https://doi.org/10.2174/1389200221666200103092719
  3. Presenilin1 exerts antiproliferative effects by repressing the Wnt/β-catenin pathway in glioblastoma vol.18, pp.1, 2018, https://doi.org/10.1186/s12964-019-0501-9
  4. New RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics vol.13, pp.9, 2018, https://doi.org/10.3390/pharmaceutics13091397